tbuckley/cabot-search huggingface dataset:
SuperAger Initiative: unlocking the genetic potential of exceptional longevity
Authors: Sofiya Milman, Nir Barzilai, Kara A. Wilson, Odette Van der Willik, Stephanie Lederman, Thomas Perls, Tina Gao, Aoife McGovern Leahy, Praduman Jain, Aisha Montgomery, Alan R. Shuldiner
Journal: Nature Aging (2023)
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation
Authors: Charles M. Rudin, David Balli, W. Victoria Lai, Allison L. Richards, Evelyn Nguyen, Jacklynn V. Egger, Noura J. Choudhury, Triparna Sen, Andrew Chow, John T. Poirier, William J. Geese, Matthew D. Hellmann, Ann Forslund
Journal: Journal of Thoracic Oncology (2023)
The indirect pathway of the basal ganglia promotes transient punishment but not motor suppression
Authors: Brian R. Isett, Katrina P. Nguyen, Jenna C. Schwenk, Jeff R. Yurek, Christen N. Snyder, Maxime V. Vounatsos, Kendra A. Adegbesan, Ugne Ziausyte, Aryn H. Gittis
Journal: Neuron (2023)
Pregnancy in primary immunodeficiency diseases: The PREPI study
Authors: Elise Mallart, Ugo Françoise, Marine Driessen, Stéphane Blanche, Olivier Lortholary, Agnès Lefort, Marion Caseris, Alain Fischer, Nizar Mahlaoui, Caroline Charlier, Karima Amazzough, Yves Bertrand, David Boutboul, Émilie Catherinot, Olivia Chandesris, Morgane Cheminant, Anne Couderc, Maud D’Aveni, Richard Delarue, Claire Fieschi, Laurent Frenzel, Lionel Galicier, Martine Gardembas, Cécile Goujard, Romain Gounot, Olivier Hermine, Arnaud Jaccard, Olivier Lambotte, Fanny Lanternier, Romain Levy, Marion Malphettes, Ambroise Marcais, Luc Mouthon, Eric Oksenhendler, Antoinette Perlat, Capucine Picard, Viviane Queyrel, Maris Robin, Felipe Suarez, Jean François Viallard
Journal: Journal of Allergy and Clinical Immunology (2023)
Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis
Authors: Natalia Alkon, Frank P. Assen, Tamara Arnoldner, Wolfgang M. Bauer, Marco A. Medjimorec, Lisa E. Shaw, Katharina Rindler, Gregor Holzer, Philipp Weber, Wolfgang Weninger, Christian Freystätter, Sumanth Chennareddy, Tamar Kinaciyan, Matthias Farlik, Constanze Jonak, Johannes Griss, Christine Bangert, Patrick M. Brunner
Journal: Journal of Allergy and Clinical Immunology (2023)
Table of Contents
Authors: Adeera Levin, Ikechi Okpechi, Fergus Caskey, Chih-Wei Yang, Marcello Tonelli, Vivekanand Jha, Michael Stokes, Wai Ping, Alicia Chan, Matthew Worthley, P Coates, Thomas Mavrakanas, Olivia Lenoir, Tobias Huber, Pierre-Louis Tharaux, Andrea Remuzzi, Masaomi Nangaku, Agathe Truchot, Marc Raynaud, Alexandre Loupy, Francesco Locatelli, Lucia Vecchio, Emma O'lone, Fred Apple, James Burton, Jonathan Craig, Christopher Defilippi, Derek Forfang, Karen Hicks, Kenneth Mahaffey, Patrick Mark, Patrick Rossignol, Nicole Scholes-Robertson, Allison Jaure, Andrea Viecelli, Angela Wang, David Wheeler, David White, Wolfgang Winkelmayer, Charles Herzog, Bruno Ranchin, Claus Schmitt, Bradley Warady, Christoph Licht, Hiroshi Hataya, Enrico Vidal, Johan Vande, Rukshana Shroff
Journal: Kidney International (2023)
Corrigendum to “Ttc21b deficiency attenuates autosomal dominant polycystic kidney disease in a kidney tubular- and maturation-dependent manner.” Kidney Int. 2022;102:577–591
Authors: Wei Wang, Luciane M. Silva, Henry H. Wang, Matthew A. Kavanaugh, Tana S. Pottorf, Bailey A. Allard, Damon T. Jacobs, Ruochen Dong, Joseph T. Cornelius, Aakriti Chaturvedi, Katherine I. Swenson-Fields, Timothy A. Fields, Michele T. Pritchard, Madhulika Sharma, Chad Slawson, Darren P. Wallace, James P. Calvet, Pamela V. Tran
Journal: Kidney International (2023)
Markers of epidemiological success of methicillin-resistant Staphylococcus aureus isolates in European populations
Authors: Valérie O. Baede, Arya Gupta, Gwenan M. Knight, Leo M. Schouls, Ken Laing, Mehri Tavakol, Anaïs Barray, Sake J. de Vlas, Anneke S. de Vos, Antoni P.A. Hendrickx, Madeeha Khan, Mirjam E. Kretzschmar, Willem J.B. van Wamel, Gérard Lina, Francois Vandenesch, Margreet C. Vos, Adam A. Witney, Jean-Philippe Rasigade, Jodi A. Lindsay
Journal: Clinical Microbiology and Infection (2023)

ObjectivesMethicillin-resistant Staphylococcus aureus (MRSA) infections impose a considerable burden on health systems, yet there is remarkable variation in the global incidence and epidemiology of MRSA. The MACOTRA consortium aimed to identify bacterial markers of epidemic success of MRSA isolates in Europe using a representative MRSA collection originating from France, the Netherlands and the United Kingdom.MethodsOperational definitions of success were defined in consortium meetings to compose a balanced strain collection of successful and sporadic MRSA isolates. Isolates were subjected to antimicrobial susceptibility testing and whole-genome sequencing; genes were identified and phylogenetic trees constructed. Markers of epidemiological success were identified using genome-based time-scaled haplotypic density analysis and linear regression. Antimicrobial usage data from ESAC-Net was compared with national MRSA incidence data.ResultsHeterogeneity of MRSA isolate collections across countries hampered the use of a unified operational definition of success; therefore, country-specific approaches were used to establish the MACOTRA strain collection. Phenotypic antimicrobial resistance varied within related MRSA populations and across countries. In time-scaled haplotypic density analysis, fluoroquinolone, macrolide and mupirocin resistance were associated with MRSA success, whereas gentamicin, rifampicin and trimethoprim resistance were associated with sporadicity. Usage of antimicrobials across 29 European countries varied substantially, and β-lactam, fluoroquinolone, macrolide and aminoglycoside use correlated with MRSA incidence.DiscussionOur results are the strongest yet to associate MRSA antibiotic resistance profiles and antibiotic usage with the incidence of infection and successful clonal spread, which varied by country. Harmonized isolate collection, typing, resistance profiling and alignment with antimicrobial usage over time will aid comparisons and further support country-specific interventions to reduce MRSA burden.
5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique
Authors: Gregg W. Stone, Dean J. Kereiakes, Tommaso Gori, D. Christopher Metzger, Bernardo Stein, Matthew Erickson, Jan Torzewski, Ameer Kabour, Guy Piegari, Jeffrey Cavendish, Barry Bertolet, Kelly A. Stockelman, Nick E.J. West, Ori Ben-Yehuda, James W. Choi, Steven O. Marx, John A. Spertus, Stephen G. Ellis
Journal: Journal of the American College of Cardiology (2023)

Bioresorbable vascular scaffolds (BVS) were designed to improve late event-free survival compared with metallic drug-eluting stents. However, initial trials demonstrated worse early outcomes with BVS, in part due to suboptimal technique. In the large-scale, blinded ABSORB IV trial, polymeric everolimus-eluting BVS implanted with improved technique demonstrated noninferior 1-year outcomes compared with cobalt chromium everolimus-eluting stents (CoCr-EES).
Investigating One Health risks for human colonisation with extended spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Malawian households: a longitudinal cohort study
Authors: Derek Cocker, Kondwani Chidziwisano, Madalitso Mphasa, Taonga Mwapasa, Joseph M Lewis, Barry Rowlingson, Melodie Sammarro, Winnie Bakali, Chifundo Salifu, Allan Zuza, Mary Charles, Tamandani Mandula, Victor Maiden, Stevie Amos, Shevin T Jacob, Henry Kajumbula, Lawrence Mugisha, David Musoke, Rachel Byrne, Thomas Edwards, Rebecca Lester, Nicola Elviss, Adam P Roberts, Andrew C Singer, Christopher Jewell, Tracy Morse, Nicholas A Feasey
Journal: The Lancet Microbe (2023)

Low-income countries have high morbidity and mortality from drug-resistant infections, especially from enteric bacteria such as Escherichia coli. In these settings, sanitation infrastructure is of variable and often inadequate quality, creating risks of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales transmission. We aimed to describe the prevalence, distribution, and risks of ESBL-producing Enterobacterales colonisation in sub-Saharan Africa using a One Health approach.
Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations
Authors: Liane S Canas, Erika Molteni, Jie Deng, Carole H Sudre, Benjamin Murray, Eric Kerfoot, Michela Antonelli, Khaled Rjoob, Joan Capdevila Pujol, Lorenzo Polidori, Anna May, Marc F Österdahl, Ronan Whiston, Nathan J Cheetham, Vicky Bowyer, Tim D Spector, Alexander Hammers, Emma L Duncan, Sebastien Ourselin, Claire J Steves, Marc Modat
Journal: The Lancet Digital Health (2023)

Self-reported symptom studies rapidly increased understanding of SARS-CoV-2 during the COVID-19 pandemic and enabled monitoring of long-term effects of COVID-19 outside hospital settings. Post-COVID-19 condition presents as heterogeneous profiles, which need characterisation to enable personalised patient care. We aimed to describe post-COVID-19 condition profiles by viral variant and vaccination status.
Reduced Left Atrial Rotational Flow Is Independently Associated With Embolic Brain Infarcts
Authors: Marco Spartera, Antonio Stracquadanio, Guilherme Pessoa-Amorim, George Harston, Sara Mazzucco, Victoria Young, Adam Von Ende, Aaron T. Hess, Vanessa M. Ferreira, James Kennedy, Stefan Neubauer, Barbara Casadei, Rohan S. Wijesurendra
Journal: JACC. Cardiovascular imaging (2023)

Up to 25% of embolic strokes occur in individuals without atrial fibrillation (AF) or other identifiable mechanisms. To assess whether left atrial (LA) blood flow characteristics are associated with embolic brain infarcts, independently of AF. The authors recruited 134 patients: 44 with a history of ischemic stroke and 90 with no history of stroke but CHA2DS2VASc (congestive heart failure, hypertension, age ≥75 [doubled], diabetes, stroke [doubled], vascular disease, age 65 to 74, and sex category [female]) score ≥1. Cardiac magnetic resonance (CMR) evaluated cardiac function and LA 4-dimensional flow parameters, including velocity and vorticity (a measure of rotational flow), and brain magnetic resonance imaging (MRI) was performed to detect large noncortical or cortical infarcts (LNCCIs) (likely embolic), or nonembolic lacunar infarcts. Patients (41% female; age 70 ± 9 years) had moderate stroke risk (median CHA2DS2VASc = 3, Q1-Q3, 2-4). Sixty-eight (51%) had diagnosed AF, of whom 58 (43%) were in AF during CMR. Thirty-nine (29%) had ≥1 LNCCI, 20 (15%) had ≥1 lacunar infarct without LNCCI, and 75 (56%) had no infarct. Lower LA vorticity was significantly associated with prevalent LNCCIs after adjustment for AF during CMR, history of AF, CHA2DS2VASc score, LA emptying fraction, LA indexed maximum volume, left ventricular ejection fraction, and indexed left ventricular mass (odds ratio [OR]: 2.06 [95% CI: 1.08-3.92 per SD]; P = 0.027). By contrast, LA flow peak velocity was not significantly associated with LNCCIs (P = 0.21). No LA parameter was associated with lacunar infarcts (all P > 0.05). Reduced LA flow vorticity is significantly and independently associated with embolic brain infarcts. Imaging LA flow characteristics may aid identification of individuals who would benefit from anticoagulation for embolic stroke prevention, regardless of heart rhythm.
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues
Authors: Annet N. Linders, Itamar B. Dias, Ekaterina S. Ovchinnikova, Mathilde C.S.C. Vermeer, Martijn F. Hoes, George Markousis Mavrogenis, Frederik E. Deiman, Karla F. Arevalo Gomez, Jacqueline M. Bliley, Jamil Nehme, Aryan Vink, Jourik Gietema, Rudolf A. de Boer, Daan Westenbrink, Herman H.W. Sillje, Denise Hilfiker-Kleiner, Linda W. van Laake, Adam W. Feinberg, Marco Demaria, Nils Bomer, Peter van der Meer
Journal: JACC CardioOncology (2023)

Doxorubicin is an essential cancer treatment, but its usefulness is hampered by the occurrence of cardiotoxicity. Nevertheless, the pathophysiology underlying doxorubicin-induced cardiotoxicity and the respective molecular mechanisms are poorly understood. Recent studies have suggested involvement of cellular senescence.The aims of this study were to establish whether senescence is present in patients with doxorubicin-induced cardiotoxicity and to investigate if this could be used as a potential treatment target.Biopsies from the left ventricles of patients with severe doxorubicin-induced cardiotoxicity were compared with control samples. Additionally, senescence-associated mechanisms were characterized in 3-dimensional dynamic engineered heart tissues (dyn-EHTs) and human pluripotent stem cell-derived cardiomyocytes. These were exposed to multiple, clinically relevant doses of doxorubicin to recapitulate patient treatment regimens. To prevent senescence, dyn-EHTs were cotreated with the senomorphic drugs 5-aminoimidazole-4-carboxamide ribonucleotide and resveratrol.Senescence-related markers were significantly up-regulated in the left ventricles of patients with doxorubicin-induced cardiotoxicity. Treatment of dyn-EHTs resulted in up-regulation of similar senescence markers as seen in the patients, accompanied by tissue dilatation, decreased force generation, and increased troponin release. Treatment with senomorphic drugs led to decreased expression of senescence-associated markers, but this was not accompanied by improved function.Senescence was observed in the hearts of patients with severe doxorubicin-induced cardiotoxicity, and this phenotype can be modeled in vitro by exposing dyn-EHTs to repeated clinically relevant doses of doxorubicin. The senomorphic drugs 5-aminoimidazole-4-carboxamide ribonucleotide and resveratrol prevent senescence but do not result in functional improvements. These findings suggest that preventing senescence by using a senomorphic during doxorubicin administration might not prevent cardiotoxicity.
Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys
Authors: Felix Sayinzoga, Vanessa Tenet, Daniëlle A M Heideman, Hassan Sibomana, Marie-Chantal Umulisa, Silvia Franceschi, Jean de Dieu Hakizimana, Gary M Clifford, Iacopo Baussano
Journal: The Lancet Global Health (2023)

Rwanda was the first African country to implement national human papillomavirus (HPV) vaccination (against types HPV6, 11, 16, and 18). In 2011, a school-based catch-up programme was initiated to vaccinate girls aged younger than 15 years but it also reached older girls in schools. We aimed to estimate the population-level effect of HPV vaccination on HPV prevalence. Cross-sectional surveys were done between July, 2013, and April, 2014 (baseline), and between March, 2019, and December, 2020 (repeat), in sexually active women aged 17-29 years at health centres in the Nyarugenge District of Kigali, Rwanda. HPV prevalence was assessed in cervical cell samples collected by a health-care worker in PreservCyt solution (Cytyc, Boxbourough, MA, USA) and tested using a general primer (GP5+ or GP6+)-mediated PCR. Adjusted overall, total, and indirect (herd immunity) vaccine effectiveness was computed as the percentage of HPV detection among all women and among unvaccinated women. 1501 participants completed the baseline survey and 1639 completed the repeat survey. HPV vaccine-type prevalence in participants aged 17-29 years decreased from 12% (173 of 1501) in the baseline survey to 5% (89 of 1639) in the repeat survey, with an adjusted overall vaccine effectiveness of 47% (95% CI 31 to 60) and an adjusted indirect vaccine effectiveness of 32% (9 to 49). Among participants aged 17-23 years, who were eligible for catch-up vaccination, the adjusted overall vaccine effectiveness was 52% (35 to 65) and the adjusted indirect vaccine effectiveness was 36% (8 to 55), with important heterogeneity according to education (overall vaccine effectiveness was 68% [51 to 79] in participants with ≥6 years of school completed and 16% [-34 to 47] in those with <6 years) and HIV status (overall vaccine effectiveness was 55% [36 to 69] for HIV-negative participants and 24% [-62 to 64] for HIV-positive participants). In Rwanda, the prevalence of vaccine-targeted HPV types has been significantly decreased by the HPV vaccine programme, most notably in women who were attending school during the catch-up programme in 2011. HPV vaccine coverage and population-level impact is expected to increase in future cohorts who are eligible for routine HPV vaccination at age 12 years. Bill & Melinda Gates Foundation.
Prediction of Coronary Heart Disease Events in Blood or Marrow Transplantation Recipients
Authors: Radhika Gangaraju, Yanjun Chen, Lindsey Hageman, Wendy Landier, Nora Balas, Elizabeth Ross, Liton Francisco, Alysia Bosworth, Hok Sreng Te, F. Lennie Wong, Daniel J. Weisdorf, Ravi Bhatia, Stephen J. Forman, Saro H. Armenian, Smita Bhatia
Journal: JACC CardioOncology (2023)

The long-term risk of coronary heart disease (CHD) and clinical models that predict this risk remain understudied in blood or marrow transplantation (BMT) recipients.
Digital health technology in clinical trials
Authors: Mirja Mittermaier, Kaushik P. Venkatesh, Joseph C. Kvedar
Journal: npj Digital Medicine (2023)

Digital health technologies (DHTs) have brought several significant improvements to clinical trials, enabling real-world data collection outside of the traditional clinical context and more patient-centered approaches. DHTs, such as wearables, allow the collection of unique personal data at home over a long period. But DHTs also bring challenges, such as digital endpoint harmonization and disadvantaging populations already experiencing the digital divide. A recent study explored the growth trends and implications of established and novel DHTs in neurology trials over the past decade. Here, we discuss the benefits and future challenges of DHT usage in clinical trials.
The Association between Obesity and Asthma
Authors: Tim J. T. Sutherland, Jan O. Cowan, Sarah Young, Ailsa Goulding, Andrea M. Grant, Avis Williamson, Karen Brassett, G. Peter Herbison, D. Robin Taylor
Journal: American Journal of Respiratory and Critical Care Medicine (2008)

Rationale: Both obesity and asthma are common conditions, and both are characterized by the presence of inflammation. Animal studies suggest that the development of airway hyperresponsiveness with antigen challenge is exaggerated with obesity. However, clear evidence for either an additive or a synergistic pathologic interaction between obesity and asthma is lacking in humans.Objectives: To identify whether an interaction between systemic and local inflammation occurs in obese subjects with asthma in a controlled observational study.Methods: We studied 79 women: obese patients with asthma (n = 20), normal-weight patients with asthma (n = 19), obese patients without asthma (n = 20), and normal-weight patients without asthma (n = 20). After corticosteroid withdrawal, between-group differences in spirometric values, lung volumes, exhaled nitric oxide, induced sputum cell counts, and biomarkers of inflammation in sputum supernatant and blood were measured, and interactions explored.Measurements and Main Results: Markers of systemic inflammation were increased with obesity, and Th2 cytokines were increased with asthma, but no important interactions were identified. Obesity adversely affected lung function with increases in functional residual capacity and residual volume in obese but not normal-weight patients with asthma, with a significant obesity by asthma interaction.Conclusions: The link between obesity and asthma is unlikely to be explained by enhancement of the "classical" forms of airway inflammation resulting from the systemic inflammatory effects of obesity itself. Other mechanisms, possibly related to innate immunity, may explain the relationship between obesity and asthma.
Examining the relationship between armed conflict and coverage of maternal and child health services in 35 countries in sub-Saharan Africa: a geospatial analysis
Authors: Felix Amberg, Collins Chansa, Hamidou Niangaly, Osman Sankoh, Manuela De Allegri
Journal: The Lancet Global Health (2023)

Armed conflict is on the rise in sub-Saharan Africa and affects public infrastructures, including health systems, although evidence on population health is sparse. We aimed to establish how these disruptions ultimately affect health service coverage.We geospatially matched Demographic and Health Survey data with the Uppsala Conflict Data Program Georeferenced Events Dataset, covering 35 countries for the period from 1990 to 2020. We relied on linear probability models with fixed effects to capture the effect of nearby armed conflict (within 50 km of the survey cluster) on four service coverage indicators along the continuum of maternal and child health care. We also investigated effect heterogeneity by varying conflict intensity and duration, and sociodemographic status.The estimated coefficients represent the decrease in the probability (in percentage points) of the child or their mother being covered by the respective health service following deadly conflicts within 50 km. Any nearby armed conflict was associated with reduced coverage for all examined health services, with the exception of early antenatal care: early antenatal care (-0·5 percentage points, 95% CI -1·1 to 0·1), facility-based delivery (-2·0, -2·5 to -1·4), timely childhood vaccination (-2·5, -3·1 to -1·9), and treatment of common childhood illnesses (-2·5, -3·5 to -1·4). For all four health services, the negative effects increased for high-intensity conflicts and were significant throughout. When examining conflict duration, we did not find negative effects on the treatment of common childhood illnesses in prolonged conflicts. The analysis on effect heterogeneity revealed that, except for timely childhood vaccination, the negative effects of armed conflict on health service coverage were more pronounced in urban settings.Our findings suggest that health service coverage is significantly affected by contemporaneous conflict, but health systems can adapt to provide routine services, such as child curative services, in situations of prolonged conflict. Our analysis underlines the importance of studying health service coverage during conflict both at the finest possible scales and across different indicators, pointing at the need for differential policy interventions.None.For the French and Portuguese translations of the abstract see Supplementary Materials section.